Searchable abstracts of presentations at key conferences in endocrinology

ea0056s13.2 | The colours of fat | ECE2018

Adipose tissue browning in mice and men

Kiefer Florian

Promotion of brown adipose tissue (BAT) activity or browning of white adipose tissue has shown great potential as anti-obesity strategy in numerous preclinical models. The discovery of active BAT in humans and the recent advances in the understanding of human BAT biology and function have sparked this field of research. Pharmacological stimulation of energy expenditure to counteract obesity has always been an intriguing therapeutic concept; the identification of the specific m...

ea0032p728 | Obesity | ECE2013

Serum- and glucocorticoid-regulated kinase 1 in obesity-related adipose tissue and peripheral inflammation

Reiter Marie Helene , Kiefer Florian , Zeyda Maximilian , Kopecky Chantal , Stulnig Thomas , Luger Anton , Vila Greisa

The serum- and glucocorticoid-regulated kinase 1 (Sgk1) is a direct transcriptional target of glucocorticoids and is post-translationally activated by the insulin/IGF1 pathway. Distinct polymorphisms in the Sgk1 gene are associated with increased body weight and type 2 diabetes. Here we investigate the expression and regulation of Sgk1 in human obesity.In both omental and subcutaneous human adipose tissue, Sgk1 expression is significantly increased in 20...

ea0022p717 | Obesity | ECE2010

Characterisation of serum and glucocorticoid-induced kinase 1 in adipose tissue

Vila Greisa , Kiefer Florian , Reiter Marie Helene , Zeyda Maximilian , Stulnig Thomas M , Luger Anton

Serum and glucocorticoid-induced kinase 1 (Sgk1) is an early transcriptional target of glucocorticoids with antiapoptotic effects. Sgk1 becomes active after phosphorylation by growth factors such as insulin and IGF1 through the PI3 kinase/PDK1 pathway. Activated Sgk1 increases the cellular uptake of glucose by increasing the membrane abundance of glucose transporters GLUT1 and GLUT4. Here we present data on the expression and regulation of Sgk1 in adipose tissue using three di...

ea0073pep4.8 | Presented ePosters 4: Reproductive and Developmental Endocrinology | ECE2021

Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21‑hydroxylase deficiency in Europe

Nowotny Hanna F. , Blankenstein Oliver , Neumann Uta , Ahmed S. Faisal , Allen Stephanie , Baronio Federico , Battelino Tadej , Bertherat Jérôme , Bonomi Marco , de la Perrière Aude Brac , Tardy Véronique , Brucker Sara , Cappa Marco , Chanson Philippe , Bouvattier Claire , Colao Annamaria , Cools Martine , Davies Justin , Fenske Wiebke K. , Ghigo Ezio , Højbjerg Gravholt Claus , Hübner Angela , Husebye Eystein Sverre , Juul Anders , Kiefer Florian W. , Léger Juliane , Meyer Gesine , Phylactou Leonidas A. , Rohayem Julia , Russo Gianni , Scaroni Carla , Touraine Philippe , Unger Nicole , Hedi L. Claahsen-van der Grinten , Vojtková Jarmila , Yeste Diego , Günther Dörr Helmut , Lajic Svetlana , Reisch Nicole

BackgroundPrenatal dexamethasone treatment (Pdex) has been used since the 1980s to prevent virilization in female offspring suspected to have congenital adrenal hyperplasia (CAH). However, due to lack of strong evidence for its best practice as well as limited data regarding longterm adverse effects, use of dex is highly controversial. This study reveals the current medical practice regarding Pdex in female fetuses at risk of CAH due to 21hydroxylase def...